Enliven Therapeutics, Inc. (ELVN), a company focused on the discovery and development of small molecule therapeutics, said on Friday that it has commenced an underwritten public offering of $200 million of shares and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares.
In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares.
All of the shares and pre-funded warrants are being offered by Enliven.
Jefferies, Goldman Sachs & Co. LLC, TD Cowen and Mizuho are acting as joint book-running managers, while LifeSci Capital is acting as lead manager for the proposed offering.
ELVN was down by 2.34% at $19.20 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.